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A B S T R A C T
Background: Ovarian tumors are a heterogeneous group of neoplasm of epithelial, stromal, and germ cell origin. Even in a 
single class of tumor, there exists inherent heterogeneity with biological behavior ranging from benign to the highly aggressive 
malignant tumor. The management of the patient also depends on the histological type of the tumor. These facts fascinated 
and prompted us to undertake the present study. Aim: To analyze the modes of presentation and various histopathological 
patterns of ovarian tumor. Materials and Methods: It was a retrospective observational study. The study was conducted in 
Department of Pathology, B. J. Medical College Pune, India from July 2006 to June 2011. All the histopathology slides of ovarian 
tumors during the study period were retrieved and reviewed along with the patient’s demographics, clinical features, and gross 
findings. Data thus collected were analyzed. Results: A total of 226 cases of ovarian tumors out of 1098 cases of female genital 
cancers were studied. Age ranged from 12 to 80 years. The surface epithelial tumors were the most common ovarian tumor 
constituting 163 cases (72.1%), followed by germ cell tumors 45 cases (19.9%). The most common complaint in the present study 
was pain in the abdomen (115 cases, 50.9%) irrespective of the nature of the ovarian tumor. Bilaterality was common in malignant 
tumors (66.7%, 16/24). Right and left side was almost equally affected among unilateral tumors. The size of the tumor varied 
from 3 to 32 cm. Conclusions: By knowing clinical data, sonography findings, and gross features, we can narrow our differential 
diagnosis and reach to the final microscopic diagnosis in most of the cases in very cost‑effective manner.
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INTRODUCTION
Ovarian cancer accounts for about 3% of all cancers in 
women. According to the surveillance epidemiology and 
end results data, ovarian tumors represent about 27% of all 
female genital cancers and account for 52% of deaths caused 
by female genital cancers.[1] The increased risk of ovarian 
cancer particularly of surface epithelial tumors (SETs) 
is associated with use of hormone replacement 
therapy (HRT),[2] tobacco consumption,[3] family history 
of ovarian cancer and breast cancer,[4] and mutation of 
BRCA1 and/or BRCA2.[4] The protective factors are the use 
of oral contraceptive pills (OCPs) and multiparity not only 
in the general population but also significantly reduces the 
risk in BRCA1/BRCA2 carriers.[5]
Of all the gynecological cancers, ovarian tumors represent 
the greatest challenge to clinicians because it is very 
difficult to diagnose it in early stage due to its nonspecific 
symptoms and even asymptomatic nature in many cases. 
On the other hand, ovarian tumors at an advanced stage 
are easy to diagnose but associated with poor prognosis 
despite advances in surgery, chemotherapy, and more 
recently, targeted therapy. Ovarian tumors are also a 
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constant source of confusion to the pathologists because of 
the wide spectrum of clinical and morphological features. 
Further, certain nonneoplastic lesions of ovary frequently 
form a pelvic mass and often associated with abnormal 
hormonal manifestations, thus potentially mimicking 
ovarian neoplasm.
Most ovarian tumors cannot be confidently distinguished 
from one another on the basis of their clinical or gross 
characteristics alone, although it provides important 
diagnostic clues in formulating a differential diagnosis. One 
of the most important clinical features is the age of the 
patient.[2] The laterality also provides a clue to their nature, 
for example, tumors in the sex cord stromal category are 
almost always confined to single ovary while most of the 
metastatic tumors are bilateral. Gross features also help in 
differential diagnosis and represent the integral behavior 
of tumor, like most benign tumors of epithelial category 
are cystic, on the other hand, the finding of solid element 
and papillary projections make malignancy more likely. 
Nevertheless, accurate diagnosis primarily depends on the 
wide range of microscopic features they exhibit.[6]
Determination of various histological patterns of ovarian 
tumors is also very important for management of the 
patient, as the diagnosis and prognosis of ovarian tumors 
depend upon its histological type. Thus, we conducted 
the study to analyze the frequency and clinicopathological 
spectrum of ovarian tumors.
MATERIALS AND METHODS
This case series cover 5-year period from July 2006 to 
June 2011. Before conducting the study, we have taken 
approval from Institutional Ethics Committee B. J. Medical 
College and Sassoon General Hospital, Pune and have 
taken informed consent from patients. We performed a 
retrospective analysis of all patients diagnosed with ovarian 
tumors during this period. Nonneoplastic lesions of ovary 
were excluded from the study. Clinical data (age, site, 
clinical features, and tumor markers level) and gross findings 
were obtained from the histopathology record section of 
the institute, and hematoxylin and eosin-stained slides 
were retrieved and reviewed. Where necessary, blocks were 
recut, stained, and reviewed. All the cases of ovarian tumors 
were classified according to the World Health Organization 
classification of tumors 2003.[7] Data collected were analyzed.
RESULTS
Of 1098 cases of female genital tract cancers, 226 cases of 
ovarian cancers (20.6%) were diagnosed. In our study, we found 
possible causal/risk factor in only 26 cases. The 3 patients are 
nulligravida presented with primary infertility, 12 patients 
have history of tobacco chewing, 4 patients have family 
history of breast and/or ovarian carcinoma in first degree 
relatives, and seven postmenopausal women have taken 
HRT for at least 6 months. Although OCPs are believed to 
the protective for ovarian carcinoma, but in our study, we 
found total 24 cases of ovarian carcinoma, 18 cases belongs 
to the SETs and 6 cases to the sex cord-stromal category 
have taken OCPs during her life for at least 6 months.
The most common histological type was SETs in our 
study. Distribution of ovarian neoplasm according to 
histological type listed in Table 1. Benign tumors were the 
most common accounting for 61.1% (138 cases/226 cases). 
Among these, mucinous cystadenoma (42 cases/138 cases, 
30.4%) was the most common. A total 16 cases (7.1%) of 
borderline category and 72 cases (31.9%) of malignant 
ovarian tumors out of total 226 cases were diagnosed. The 
peak incidence of ovarian tumors was seen in the third and 
fifth decades accounting for 22.6% (51 cases/226 cases) and 
26.5% (60/226), respectively. Germ cell tumors were common 
in the age group 11–30 years with total 26 cases [Table 2]. 
One case of metastatic tumor (Krukenberg tumor) was 
observed in very young female, 27-year-old, with primary 
gastric cancer [Figure 1].
Of 226 cases, the most common presenting complaint was 
pain in abdomen (115 cases, 50.9%) followed by the lump 
Table 1: Frequency of main histological types of ovarian tumors
Type Number of cases Percentage
Surface epithelial tumors 163 72.1
Germ cell tumors 45 19.2
Sex cord stromal tumors 16 7.1
Metastatic 02 0.9
Table 2: Age-wise distribution of ovarian tumors
Types of tumor Age (in years)
1-10 11-20 21-30 31-40 41-50 51-60 >60
Benign serous tumor (n=53) 0 1 12 19 13 4 4
Borderline serous tumor (n=2) 0 0 1 0 1 0 0
Malignant serous tumor (n=31) 0 0 0 1 10 9 11
Benign mucinous tumor (n=42) 0 1 15 8 12 2 4
Borderline mucinous tumor (n=14) 0 0 1 4 5 2 2
Malignant mucinous tumor (n=16) 0 1 0 0 9 4 2
Clear cell carcinoma (n=1) 0 0 0 0 1 0 0
Endometrioid carcinoma (n=3) 0 0 0 0 3 0 0
Benign Brenner tumor (n=1) 0 0 0 0 0 1 0
Dysgerminoma (n=3) 0 0 2 1 0 0 0
Mature cystic teratoma (n=34) 0 1 16 12 2 2 1
Struma ovarii (n=1) 0 0 0 0 1 0 0
Immature teratoma (n=1) 0 1 0 0 0 0 0
Yolk sac tumor (n=3) 0 3 0 0 0 0 0
Mixed germ cell tumor (n=3) 0 1 2 0 0 0 0
Granulosa cell tumor (n=9) 0 0 0 1 3 3 2
Fibroma (n=5) 0 0 1 1 0 2 1
Sertoli‑Leydig cell tumor (n=1) 0 0 0 1 0 0 0
Steroid cell tumor (n=1) 0 1 0 0 0 0 0
Krukenberg tumor (n=2) 0 0 1 0 0 0 1
Total 0 10 51 48 60 29 28
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in abdomen (66 cases, 29.2%) irrespective of the nature 
of the tumor. Ascites, anorexia, and weight loss were 
more commonly observed in borderline and malignant 
tumors. Menstrual irregularities, excessive bleeding, and 
postmenopausal bleeding were the presenting complaints 
in the 27 cases (11.9%). Totally, 16 cases of ovarian tumors 
were incidentally found all were benign; the most common 
finding in these was serous cystadenoma (8 cases). None 
of the malignant tumor was diagnosed incidentally. Totally 
3 cases, one of serous cystadenoma, one of mucinous 
cystadenoma, and one of well-differentiated Sertoli-Leydig 
cell tumor was presented with acute abdomen. We also 
found 1 case of steroid cell tumor with typical symptoms 
of virilization.
Cancer antigen (CA) 125 value was available in total 27 cases 
of SETs. Of 22 malignant tumors, 20 cases showed CA 125 
value >35 U/ml, whereas 3 cases out of 5 benign tumors also 
showed more value than cut-off of 35 U/ml indicating CA 125 
as sensitive marker (sensitivity 90.9%) preoperatively but 
not specific (40%). Diagnostic accuracy was 81.5% (analysis 
had done using SPSS inc; Chicago 17.0 version  software). 
Alpha fetoprotein (AFP) level was available only in 3 cases 
of germ cell tumors, 2 cases of yolk sac tumor (YST), and 
1 case of mixed germ cell tumor, having values 960 ng/ml, 
920 ng/ml, and 840 ng/ml, respectively.
The most common surgical specimen in benign and 
borderline ovarian tumors was cystectomy constituting 
57.3% (79/138) and 43.8% (7/16), respectively, whereas 
in malignant ovarian tumors, the most common surgical 
specimen was transabdominal hysterectomy with bilateral 
salpingo-oophorectomy (TAH + BSO) with or without 
omentum constituting 80.6% (58/72).
Size range was 3–32 cm in the present study. The largest 
tumor in our study was borderline mucinous cystadenoma 
sized 32 cm found. Size-wise distribution of various ovarian 
tumors is listed in Table 3.
On gross inspection, totally 115 cases out of 138 cases 
of benign tumors and all 16 cases of borderline tumors 
were cystic in consistency, whereas in malignant tumors, 
most of the tumors showed (47 cases out of 72 cases) 
partly cystic and partly solid consistency. All cases of 
fibroma (5 cases), endometrioid carcinoma (3 cases), 
dysgerminoma (3 cases) [Figure 2], YST (3 cases) [Figure 3], 
metastatic tumors (2 cases), Brenner tumor (1 case), 
and steroid cell tumor (1 case) were completely solid in 
consistency. Within cystic tumors, serous tumors showed 
mainly uniloculated cyst (44 cases out of 55 cases) whereas 
in mucinous tumors, multiloculation was common 
finding (45 out of 56 cases). In 29 cases, where omentum 
was received, 5 cases of serous cystadenocarcinoma and 
Figure 1: Photomicrograph of Krukenberg tumor showing signet ring 
cells within the pools of mucin (H and E, ×400)
Figure 2: Photomicrograph of dysgerminoma showing lobules of round to 
polygonal cell with clear cytoplasm, round nuclei, and prominent nucleoli 
separated by fibrous septa infiltrated by lymphocytes (H and E, ×400)
Table 3: Size wise distribution of ovarian tumors
Types of tumor Size (in cm)
1-10 11-20 21-30 >30
Benign serous tumor (n=53) 35 13 5 0
Borderline serous tumor (n=2) 2 0 0 0
Malignant serous tumor (n=31) 20 10 1 0
Benign mucinous tumor (n=42) 17 23 2 0
Borderline mucinous tumor (n=14) 3 7 3 1
Malignant mucinous tumor (n=16) 5 7 4 0
Clear cell carcinoma (n=1) 1 0 0 0
Endometrioid carcinoma (n=3) 2 1 0 0
Benign Brenner tumor (n=1) 1 0 0 0
Dysgerminoma (n=3) 1 2 0 0
Mature cystic teratoma (n=34) 28 6 0 0
Struma ovarii (n=1) 1 0 0 0
Immature teratoma (n=1) 1 0 0 0
Yolk sac tumor (n=3) 1 1 1 0
Mixed germ cell tumor (n=3) 0 2 1 0
Granulosa cell tumor (n=9) 3 6 0 0
Fibroma (n=5) 3 2 0 0
Sertoli‑Leydig cell tumor (n=1) 0 0 0 1
Steroid cell tumor (n=1) 0 1 0 0
Krukenberg tumor (n=2) 2 0 0 0
Total 126 81 17 2
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3 cases of mucinous cystadenocarcinoma showed tumor 
deposits.
Special stain periodic-acid Schiff (PAS) was done in all cases 
of mucinous tumors to confirm intracellular mucin and in 
YST to confirm the presence of hyaline globules which are 
PAS positive.
DISCUSSION
Frequency of ovarian tumors in total surgical pathology 
specimens (21,256) in this study was 1.1% (226 cases), 
similar to Saxsena et al.[8] Among female genital tract 
malignancies, ovarian cancer constituted 20.6% next to 
the cancer of the cervix (61.2%), comparable to the study 
of Dhakal and Pradhan[9] from Nepal who reported 85.2% 
of cervical cancers and 6.4% of ovarian cancers in total 
gynecological cancers. Data were different from cancer 
statistics 2009 report by Jemal et al.[1] where the ovarian 
tumor was the leading cancer of female genital tract. This 
difference is may be due to the poor socioeconomic status, 
poor hygiene, and environmental factors in developing 
countries causing more cases of cervical cancer.
SETs of the ovary were the commonly encountered tumors 
in the study of Pilli et al.[10] and Gupta et al.[11] comparable to 
our study. For many years, it was assumed that the serous 
tumors are arising from ovarian surface epithelium (OSE) 
which is the part of the pelvic peritoneum overlies the 
ovary and lines the epithelial inclusion cyst. But in recent 
years, a new hypothesis of tubal fimbrial origin for serous 
carcinoma was given by many authors. Piek et al.[12] found the 
dysplastic (termed as tubal intraepithelial carcinoma [TIC]) and 
hyperplastic lesions on fimbriae of 11 out of 12 prophylactic 
salpingo-oophorectomy specimens removed from BRCA 
mutations carriers, and showed increased proliferation 
and over-expression of p53 similar to the high grade 
serous ovarian tumors which also showed p53 mutation. 
This hypothesis later supported by many authors.[13,14] The 
controversy whether the serous carcinomas arise from the 
tubal fimbriae or the OSE is still ongoing because none of 
the study concluded 100% positivity in favor of either the 
fimbrial or the OSE hypothesis. Therefore, dual model for 
serous tumors carcinogenesis should be followed. In our 
study, we found 31 cases of serous carcinomas but only one 
section of tube from the fimbrial end was given, and we did 
not found any TICs or hyperplastic lesion. This may be due 
to the limited section from the tube was taken.
The preponderance of benign tumors in our study was also 
similar to Pilli et al.[10] and Gupta et al.[11] The frequency of 
borderline tumors in the present study was higher than the 
Ahmad et al.,[15] Pilli et al.,[10] and Koonings et al.[16] Reason for 
these may be more sections taken from mucinous tumors as 
they show geographic variability with admixture of benign, 
borderline, and overtly malignant components in the same 
tumor, and we found >10% focus of borderline tumor to 
labeled them as borderline tumors.
In the present study, benign tumors were more common in 
the 21–40 years of age group and malignant tumors were 
more common after the 40 years of age, similar to Vora and 
Bhargav.[17] They also reported almost similar age range. The 
incidence of germ cell tumors in the first two decades was 
60% in our study which was comparable to Ahmad et al.[15] 
and Pilli et al.[10] Mature cystic teratoma [Figures 4 and 5] has 
wider age distribution with a peak incidence in the third 
and fourth decade, finding was similar with others.[10,15,16] 
In accordance with Kooning et al.[16] and Pilli et al.,[10] the 
proportion of mature cystic teratomas were decreased in 
the present study with the advancement in age. The age 
range in sex cord stromal tumors was 20–65 years with 
median 51 years in the present study as compared to 
Haroon et al.[18] who reported the median age 45 years. 
Figure 3: Photomicrograph showing cystic and reticular pattern in yolk 
sac tumor (H and E, ×100)
Figure 4: Photomicrograph of mature cystic teratoma showing 
skin, sebaceous glands, cartilage, intestinal villi, and mucous glands 
(H and E, ×40)
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Granulosa cell tumor (GCT) was common after the 40 years 
of age, Lee et al.[19] also found that >90% of GCTs occur after 
the age of 30 years in the multicenter analysis of 113 cases 
of GCT.
Irrespective of the nature of ovarian tumors, the most 
common presenting complaint in the present study was pain 
in abdomen followed by a lump in abdomen in contrast to 
other studies[10,17] which reported lump in abdomen as chief 
complaint followed by pain in the abdomen. This difference 
in symptomatology may be due to the increased awareness 
to get early medical advice and due to the availability of 
imaging techniques nowadays. Results by Wasim et al.[20] 
from Pakistan were similar. In accordance to Bhuvanesh and 
Logambal[21] and Pilli et al.,[10] ascites, anorexia, and weight 
loss were commonly associated with malignant tumors. 
Frequency of menstrual disorders was lower in our study as 
compared to others.[17,21]
For preoperative assessment of the inherent nature of 
ovarian tumors, CA 125 using >35 U/ml cut-off was not 
much helpful due to less specificity in the present study. 
Vasilev et al.[22] and Medeiros et al.[23] reported better 
specificity using same cut-off and concluded that CA 125 
was a useful preoperative test for predicting the benign 
or malignant nature of ovarian masses. The reason for the 
difference could be the smaller sample size of the present 
study as compared to the large review study of them. The 
AFP level was elevated in all 3 malignant germ cell tumors, 
and it was nearer to 1000 ng/ml; the finding was similar to 
the Kawai et al.[24]
Most of the benign and borderline tumors were 
unilateral, whereas bilaterality was common in malignant 
tumors, findings are similar to Pilli et al.[10] Among 
bilateral tumors, the most common tumor was serous 
cystadenocarcinoma [Figure 6] in the present study as well 
as in the study by Prabhakar and Maingi.[25] The question 
of the occurrence of bilateral ovarian carcinomas whether 
they arise simultaneously as primary tumors or one 
developed because of metastatic spread from another ovary 
harboring primary tumor was raised by Pejovic et al.[26] and 
Micci et al.[27] In their study, cytogenetic analysis of bilateral 
tumors has done. They concluded that most of the bilateral 
tumors showed similar karyotypic pattern suggesting the 
metastatic spread; although the side carrying the primary 
tumor could not be identified. The gross and microscopic 
features suggestive of metastatic spread or both are primary 
tumors not addressed in any of the studies. However, the 
presence of peritoneal deposits, surface growth, positive 
ascitic fluid, and difference in the size of both tumors are 
suggestive features of metastatic spread to another ovary. 
Larger tumor can be considered primary and smaller was 
secondary because it has lesser time for growth. In our 
study, we found total 24 cases of bilateral ovarian cancer 
out of 226 cases which constitute 10.6% from these 15 cases 
belong to malignant SETs category. The size of tumor in 
right and left side was almost similar in 10 cases ranging 
from 4 to 15 cm in diameter whereas in 5 cases marked 
difference in size of both sides which is 8–12 cm. All 5 cases 
showed omental deposits and positive ascitic fluid cytology 
for malignant cells. None of the case showed surface 
growth. We have no facility for a cytogenetic study to 
prove monoclonality. However, we can assume that among 
15 bilateral tumors, only 5 cases were due to metastatic 
spread from contralateral ovary because of marked variation 
in size, presence of omental deposits and ascites. But the 
question arose then why with widespread omental deposits 
and positive ascitic fluid cytology, the contralateral ovary 
was normal in unilateral malignant tumors. Hence, more 
studies should be undertaken to resolve this issue.
Side (right or left) preponderance was not found in the 
present study whereas Saxsena et al.[8] and Pilli et al.[10] 
Figure 5: Gross photograph of mature cystic teratoma showing hair tufts 
with hard cartilaginous area
Figure 6: Gross photograph of serous cystadenocarcinoma showing 
grayish white cut surface with areas of hemorrhages and necrosis
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found the right side to be more commonly involved. None 
of the case of sex cord stromal tumor was bilateral in the 
present study similar to Pilli et al.[10] whereas Prabhakar and 
Maingi[25] found bilaterality in 3 cases of sex cord stromal 
tumors.
In the present study, the most common specimen 
(as treatment modality) in malignant tumors was 
TAH + BSO (with or without omentum) In 80.6% cases. 
In the study of Randhawa and Lata,[28] it was almost similar 
(72.5%). Whereas in benign and borderline tumors fertility 
preserving surgery in the form of cystectomy, unilateral 
salpingo-oophorectomy and oophorectomy were most 
commonly attempted.
Grossly, 83.3% benign tumors were cystic; whereas 65.3% 
malignant tumors were partly cystic and partly solid, and 
30.6% were solid in consistency. Data are comparable 
with Prabhakar and Maingi[25] and Pilli et al.[10] Both of the 
studies did not report the predominantly solid consistency 
in borderline tumors similar to our study. It can be seen 
from present study that size is not an important factor in 
accessing the nature of tumor, as size range in benign, 
borderline, and malignant tumors were almost similar 
3–30 cm, 7–32 cm, and 4–25 cm, respectively.
CONCLUSION
Ovarian tumors exhibited the wide spectrum of clinical 
and histological features. Ovarian cancers are second 
most common cancer among all cancers in the female 
genital tract. SETs were the most common followed by 
germ cell tumors. Borderline tumors were encountered 
more in the mucinous category than serous. Anorexia, 
ascites, and weight loss were associated with malignant 
tumors. On grossing presence of solid element makes 
malignancy more likely. The size of the tumor was 
not related to the nature of the tumor. In the era of 
immunohistochemistry and molecular pathology, where 
the diagnosis is based on these, in the institutes with 
limited resources, these clinicomorphological features 
are very helpful for diagnosis and proper management 
of the patients.
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